March 31 (Reuters) – Novo Nordisk has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off competition from cheaper ...

BENGALURU -- Ameya Nagarajan forks out nearly 25,000 rupees ($270) every month for weight-loss drugs, 20% more than the average monthly income of a salaried Indian.

A fully-featured, console-based Cab Booking System built in Java that demonstrates 15 core Object-Oriented Programming concepts through a real-world ride-hailing simulation. The system covers ...

In a significant development for diabetes and obesity care, the patent for semaglutide - the key molecule behind blockbuster drugs like Ozempic and Wegovy, expired on March 20. Originally developed by ...

Multiple domestic pharmaceutical companies launched generic semaglutide on Saturday, a day after the drug's patent expired in India, with prices falling by as much as 90% from the branded version, ...

https://www.thehindubusinessline.com/companies/generic-versions-of-novo-nordisks-semaglutide-begin-to-flow-priced-50-80-lower-than-the-innovator/article70769849.ece ...